Trial Profile

Phase 1 study of REM 392 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REM 392 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

20 May 2025 New trial record
07 May 2025 According to Remynd media release, company has has administered the first doses of its new Alzheimer drug candidate in a clinical trial, first results expected in early July. By evaluating the safety, tolerability, and pharmacokinetics of this new drug candidate, company aim to lay the groundwork for a Phase 2 clinical trial in patients next year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com